Consun Pharmaceutical Group Overview

  • Founded
  • 1997
Founded
  • Status
  • Public
  • Employees
  • 2,649
Employees
  • Stock Symbol
  • 01681
Stock Symbol
  • Investments
  • 2
  • Share Price
  • $0.42
  • (As of Friday Closing)

Consun Pharmaceutical Group General Information

Description

Consun Pharmaceutical Group is a biotechnology company with sales operations throughout China. Its principal activities are making and selling pharmaceutical products. The company has two reportable segments: the Consun pharmaceutical segment, which is the key revenue driver, makes and sells modern Chinese medicines and medical contrast medium, and the Yulin pharmaceutical segment, which manufactures and sells traditional Chinese medicines. Consun derives revenue from kidney medicines, contrast medium, orthopedics medicines, dermatologic medicines, hepatobiliary medicines, medicines for women and children, and others.

Contact Information

Ownership Status
Publicly Held
Financing Status
Corporation
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Stock Exchange
HKG
Primary Office
  • 71, Dongpeng Avenue Eastern section
  • Guangzhou Economic and Technological Development D
  • Guangzhou, Guangdong 510760
  • China

Consun Pharmaceutical Group Timeline

2017201820192020
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Consun Pharmaceutical Group Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.42 $0.43 $0.34 - $0.63 $344M 823M 852K

Consun Pharmaceutical Group Financials Summary

In Thousands,
USD
TTM 30-Jun-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018 FY 2017 31-Dec-2017
EV 271,098 463,755 456,367 821,983
Revenue 220,808 250,149 278,745 245,671
EBITDA 14,609 30,890 105,729 91,707
Net Income 5,578 11,553 70,345 58,633
Total Assets 513,802 529,969 566,512 547,126
Total Debt 82,520 79,117 57,063 87,017
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Consun Pharmaceutical Group Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Consun Pharmaceutical Group‘s full profile, request access.

Request a free trial

Consun Pharmaceutical Group Executive Team (2)

Name Title Board Seat Contact Info
Li Kangchen Co-Founder, President & Vice Chairman
An Yubao Co-Founder, Chairman & Executive Director
To view Consun Pharmaceutical Group’s complete executive team members history, request access »

Consun Pharmaceutical Group Board Members (2)

Name Representing Role Since
00 00000 Consun Pharmaceutical Group Co-Founder, Chairman & Executive Director 000 0000
00 00000000 Consun Pharmaceutical Group Co-Founder, President & Vice Chairman 000 0000
To view Consun Pharmaceutical Group’s complete board members history, request access »

Consun Pharmaceutical Group Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Consun Pharmaceutical Group Investments & Acquisitions (2)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
0000000 00000 0000 16-Aug-2016 000000000 00000000 000.00 Drug Discovery
Guangxi Yulin Pharmaceutical 09-Nov-2015 Merger/Acquisition 00000 Drug Discovery
To view Consun Pharmaceutical Group’s complete investments and acquisitions history, request access »

Consun Pharmaceutical Group Subsidiaries (1)

Company Name Industry Location Founded
0000000 00000 0000 Drug Discovery Yulin, China 0000
To view Consun Pharmaceutical Group’s complete subsidiaries history, request access »